Technology

Non-Invasive, Real-time, Point-Of-Care

Measurements of biomarkers combined with exhaled breath analysis

Proprietary, clinically validated, algorithm provides accurate measure of sepsis risk

User friendly and portable technology allows deployment in a variety of settings: field, ambulances, nursing homes, urgent care, walk-in clinics, etc.

Key measurements include:

• Nitric Oxide (NO)
• Proprietary complimentary biomarkers

A proprietary algorithm will provide a predictive probability of sepsis risk for a given patient

Our IP position has been established with the help of a leading international law firm.

For Patients who have Sepsis: faster diagnosis and treatment to improve outcomes

• Immediate results; within ~1 minute, reduces delays in treatment (8% mortality increase with every hour)
• Patients with septic shock who receive appropriate antimicrobial therapy within 1 hour of recognition have the greatest benefit in mortality risk (J Emerg Med. 2017 Oct;53(4):588-59)

For Patients who do not have Sepsis: reduce unnecessary treatments and costs

• Screening of patients not at risk for Sepsis provides pathway for correct decision at point-of-care
• Current screening technologies are either lacking in specificity (SIRS false positives) or sensitivity (qSOFA false negatives), leading to over-prescription out of an abundance of caution.